Moxifloxacin
- Generic Name
- Moxifloxacin
- Brand Names
- Avelox, Moxeza, Vigamox
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24FN3O4
- CAS Number
- 151096-09-2
- Unique Ingredient Identifier
- U188XYD42P
- Background
Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
- Indication
For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
- Associated Conditions
- Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections
Pharmacokinetic Evaluation of Moxifloxacin IV to Enteral Switch Therapy in Intensive Care Patients
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2012-12-10
- Lead Sponsor
- University Hospital, Ghent
- Target Recruit Count
- 4
- Registration Number
- NCT00458900
- Locations
- 🇧🇪
University Hospital Ghent, Ghent, Belgium
Esomeprazole, Moxifloxacin and Amoxicilin for Rescue Therapy of Helicobacter Pylori Infection
- Conditions
- Helicobacter Pylori InfectionChronic Gastritis
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2007-04-04
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 132
- Registration Number
- NCT00455806
- Locations
- 🇩🇪
Technical University of Munich, Medical Dept. II, Munich, Germany
🇩🇪Med. Department, Jung-Stilling Krankenhaus, Siegen, Germany
🇩🇪Med. Dept. I, Gastroenterology, University Hospital, Technical University of Dresden, Dresden, Germany
A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease
- Conditions
- Pelvic Inflammatory Disease
- Interventions
- First Posted Date
- 2007-03-28
- Last Posted Date
- 2014-09-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 460
- Registration Number
- NCT00453349
Acute Cholecystitis - Early Laparoscopic Surgery Versus Antibiotic Therapy and Delayed Elective Cholecystectomy
- Conditions
- Acute Cholecystitis
- First Posted Date
- 2007-03-14
- Last Posted Date
- 2012-07-23
- Lead Sponsor
- Heidelberg University
- Target Recruit Count
- 644
- Registration Number
- NCT00447304
- Locations
- 🇩🇪
University Hospital Heidelberg, Heidelberg, Germany
Efficacy and Safety of Sequential IV/PO Moxifloxacin in Comparison to IV Levofloxacin Plus IV Ceftriaxone Followed by PO Levofloxacin, in the Treatment of Patients With Community-acquired Pneumonia
- Conditions
- Pneumonia
- Interventions
- First Posted Date
- 2007-02-06
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 738
- Registration Number
- NCT00431678
A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2012-04-05
- Lead Sponsor
- Faes Farma, S.A.
- Target Recruit Count
- 30
- Registration Number
- NCT00419783
- Locations
- 🇺🇸
MDS Pharma Services, Phoenix, Arizona, United States
Comparison of the Effect of 4th Generation Fluoroquinolones, Gatifloxacin and Moxifloxacin, on Epithelial Healing Following Photorefractive Keratectomy (PRK), A Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)
- Conditions
- Epithelium, Corneal
- Interventions
- First Posted Date
- 2006-12-20
- Last Posted Date
- 2013-07-17
- Lead Sponsor
- Walter Reed Army Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT00414011
- Locations
- 🇺🇸
Walter Reed Army Medical Center, Washington, District of Columbia, United States
Therapeutic Variables in Cataract Surgery
- Conditions
- Cataract Surgery
- First Posted Date
- 2006-12-04
- Last Posted Date
- 2007-08-21
- Lead Sponsor
- Innovative Medical
- Registration Number
- NCT00407017
- Locations
- 🇺🇸
The Center for Excellence in Eye Care, Miami, Florida, United States
Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection
- Conditions
- AbscessWound InfectionUlcerDiabetic Foot
- Interventions
- Drug: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2014-11-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 813
- Registration Number
- NCT00402727
Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells
- Conditions
- Hodgkin DiseaseMultiple MyelomaNon-Hodgkin LymphomaBacteremia
- Interventions
- Drug: placebo
- First Posted Date
- 2006-11-10
- Last Posted Date
- 2015-06-29
- Lead Sponsor
- University of Cologne
- Target Recruit Count
- 66
- Registration Number
- NCT00398411
- Locations
- 🇩🇪
Klinikum der Universität zu Köln, Köln, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.